Episode Details

Pfizer Inc. (PFE) Q2 2026 — Q2 revenue $15,034M UP 3% reported but just 1% operationally, against a $14.55B Street bar. Adjusted EPS $0.77 beat a $0.68 consensus by 13% - and came in BELOW the $0.78 earned a year earlier. GAAP was a LOSS of $(0.04) on $4.3B of intangible impairments. FY26 revenue guidance raised $500M at the midpoint to $60.5-$62.5B; adjusted EPS guidance REAFFIRMED at $2.80-$3.00. Stock +3.9% since the print, at $25.995. Pfizer beat by 13% and lost money. Adjusted EPS of $0.77 cleared a $0.68 bar - but the company earned $0.78 in the same quarter of 2025, and first-half adjusted EPS is $1.52 against $1.69, down 10%. On a GAAP basis Q2 was a $(248)M net loss, because Pfizer wrote off $4.3B of intangibles: $3.8B against the failed Phase 3 of sigvotatug vedotin, the first new ADC out of the $43B Seagen deal, and $525M retiring Oxbryta. None of it touches the adjusted number. Meanwhile $22,860M of revenue - 37% of the guide - carries a patent expiry date, starting with Eliquis in 2028. THE CALL: AVOID (3/5, A NINE-TIMES MULTIPLE ON EARNINGS THAT ARE NOT CASH) — base-case value ~$17.0 vs ~$25.995 today. KEY METRICS: - CALL: AVOID 3/5, fair value ~$17 vs the $25.995 tape (-35%). Street: 39 analysts, 15 Buy / 23 Hold / 1 Sell, $26.88 avg - which itself implies only +3%. We DIFFER on size, not direction. - Q2 revenue $15,034M (+1% operational). Adjusted EPS $0.77 vs a $0.68 bar and $0.78 a year ago. GAAP $(0.04). $4.3B of impairments: $3.8B sigvotatug vedotin, $525M Oxbryta. - 8.96x guided EPS but 18.2x EV/free cash flow. TTM FCF $10,986M vs a $9,838M dividend. LOE-exposed revenue $22,860M = 37% of guide. Tangible book NEGATIVE $33.3B. What to watch: UP: berobenatide Phase 3 data competitive with Lilly, free cash flow sustaining above $12B, or - counter-intuitively - a dividend cut that redirects $4-5B a year into the pipeline. BEAR: Eliquis U.S. erosion arriving before 2028, another impairment on a Seagen asset, or the payout ratio going back above 100% of free cash flow. Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.